Last reviewed · How we verify

VeraCept — Competitive Intelligence Brief

VeraCept (VeraCept) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: 11β-HSD2 inhibitor. Area: Endocrinology.

phase 3 11β-HSD2 inhibitor 11β-HSD2 Endocrinology Small molecule Live · refreshed every 30 min

Target snapshot

VeraCept (VeraCept) — Sebela Women's Health Inc.. VeraCept is a medication that works by inhibiting the enzyme 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2).

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
VeraCept TARGET VeraCept Sebela Women's Health Inc. phase 3 11β-HSD2 inhibitor 11β-HSD2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (11β-HSD2 inhibitor class)

  1. Sebela Women's Health Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). VeraCept — Competitive Intelligence Brief. https://druglandscape.com/ci/veracept. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators: